| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
---|---|---|---|---|---|---|---|
Age at diagnosis (years) | 56 | 57 | 54 | 53 | 55 | 55 | 62 |
NCCN risk group | High | Intermediate | High | Intermediate | Intermediate | Intermediate | Intermediate |
Preoperative PSA (ng/ml) | 4.5 | 4 | 4.9 | 5.7 | 4.20 | 10.00 | 6.80 |
Gleason score | 7 (4 + 3) | 7 (4 + 3) | 8 (4 + 4) | 7 (3 + 4) | 6 (3 + 3) | 6 (3 + 3) | 7 (3 + 4) |
Pathologic T-stage | T3b | T2c | T3a | T2 | T2c | T2c | T2c |
Pathologic N-stage | N0 | N0 | N0 | N0 | Nx | N0 (0/5) | N0 (0/8) |
Extraprostatic extension | Present | None | Present | None | Negative | Negative | Negative |
Seminal vesicle invasion | Present | None | None | None | Negative | Negative | Negative |
Operative margins | Negative | Negative | Positive | Negative | Negative | Positive | Positive |
Post-operative PSA | Undetectable | Undetectable | 0.2 | Undetectable | Detectable | 0 | 2.23 |
Time to biochemical failure (months) | 30.5 | 86.3 | 3.2 | 72.5 | 3.53 | 45.47 | 1.4 |
Adjuvant or Salvage Radiation | Adjuvant | Salvage | Salvage | Salvage | Salvage | Salvage | Salvage |
Radiation field | Prostate fossa | Prostate fossa | Prostate fossa | Prostate fossa | Prostate Fossa | Prostate fossa | Prostate fossa + LN |
Radiation dose prescription | 7200Â cGy | 7020Â cGy | 6840Â cGy | 7200Â cGy | 7020Â cGy | 6660Â cGy | 6840Â cGy |
Recurrence within 100% isodose | Yes | Yes | Yes | No (outside of contour) | Yes | Yes | Yes |
Dose to recurrence lesion | N/A | 7020Â cGy | 6840Â cGy | 4900Â cGy | 7020Â cGy | 6660Â cGy | N/A |
PSA at 18F-PSMA PET/CT (ng/ml) | 0.54 | 0.83 | 1.01 | 1.39 | 3.09 | 1.31 | 3.31 |